LABELLEFILLE

This brand name is authorized in Japan

Active ingredients

The drug LABELLEFILLE contains a combination of these active pharmaceutical ingredients (APIs):

1 Levonorgestrel
UNII 5W7SIA7YZW - LEVONORGESTREL

The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest.

Read about Levonorgestrel
2 17 alpha-Ethinylestradiol
UNII 423D2T571U - ETHINYL ESTRADIOL

Ethinylestradiol is chemically and biologically identical to endogenous human oestradiol. It substitutes for the loss of estrogen production in menopausal women, and alleviates menopausal symptoms. Estrogens prevent bone loss following menopause or ovariectomy.

Read about 17 alpha-Ethinylestradiol

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: JP 医薬品医療機器総合機構 Identifier(s): 254910BF1055, 254910BF2051

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.